https://www.selleckchem.com/pr....oducts/Rapamycin.htm
AIDS Clinical Trials Group study A5308 found reduced T-cell activation and exhaustion in HIV controllers initiating antiretroviral therapy (ART). We further assessed HIV-specific T-cell responses and post-ART viral loads. Pre-ART, the 31% of participants with persistently undetectable viremia had more robust HIV-specific T-cell responses. On ART, significant decreases were observed in a broad range of T-cell responses. Eight controllers in A5308 and the SCOPE cohort showed no viremia above the level of quantification in the first 12 w
Like
Comment
Share
